Cargando…

Leishmaniasis Vaccination: Targeting the Source of Infection

Detalles Bibliográficos
Autor principal:	Reed, Steven G.
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2001
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193470/ https://www.ncbi.nlm.nih.gov/pubmed/11489957

Ejemplares similares

Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs
por: Duthie, Malcolm S., et al.
Publicado: (2022)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
por: Wasunna, Monique, et al.
Publicado: (2016)

Addressing a clinical challenge: guidelines for the diagnosis and treatment of leishmaniasis
por: Aronson, Naomi E.
Publicado: (2017)

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis
por: Duthie, Malcolm S., et al.
Publicado: (2016)

Control of visceral leishmaniasis in East Africa: fragile progress, new threats
por: Dahl, Elin Hoffmann, et al.
Publicado: (2021)

Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection
por: Anderson, Annaliesa S., et al.
Publicado: (2016)

Premalignant Lesions as Targets for Cancer Vaccines
por: Finn, Olivera J.
Publicado: (2003)

Leishmaniasis: Path toward elimination from the Indian subcontinent
por: Karunaweera, Nadira D
Publicado: (2016)

The paradox of tegumentary leishmaniasis diagnosis: How the need for accurate and modern techniques is being addressed in low income areas
por: Kurizky, Patrícia Shu, et al.
Publicado: (2018)

Vaccines for Canine Leishmaniasis
por: Palatnik-de-Sousa, Clarisa B.
Publicado: (2012)

Vaccines for Canine Leishmaniasis
por: Foroughi-Parvar, Faeze, et al.
Publicado: (2014)

Vaccines to prevent leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2014)

Peptide Vaccines for Leishmaniasis
por: De Brito, Rory C. F., et al.
Publicado: (2018)

Determining the HPV vaccine schedule for a HIV-infected population in sub Saharan Africa, a commentary
por: Menon, Sonia, et al.
Publicado: (2018)

DNABII targeting antibodies as vaccines against biofilm diseases
por: D'Andrea, Marco M., et al.
Publicado: (2020)

Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics
por: Wei, Wen-Chi, et al.
Publicado: (2022)

Prompt and precise identification of various sources of infection in response to the prevention of malaria re-establishment in China
por: Yin, Jianhai, et al.
Publicado: (2022)

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis
por: Duthie, Malcolm S., et al.
Publicado: (2017)

Recognizing the Importance of Vaccine Confidence
por: Black, Steven
Publicado: (2016)

Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India
por: Mahajan, Raman, et al.
Publicado: (2015)

Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies
por: Mondal, Dinesh, et al.
Publicado: (2019)

Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis
por: Cecílio, Pedro, et al.
Publicado: (2017)

The Potential Benefits of HPV Vaccination in Previously Infected Women
por: Schiller, John T.
Publicado: (2016)

SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
por: Antonopoulou, Tania, et al.
Publicado: (2022)

Moving targets: COVID-19 vaccine efficacy against Omicron subvariants
por: da Silva, Maria Karolaynne, et al.
Publicado: (2022)

Role of vaccine science diplomacy in low-middle-income countries for eradicating the vaccine-preventable diseases: Targeting the “LAST MILE”
por: Bhattacharya, Sudip, et al.
Publicado: (2021)

Addressing the social issues around vaccination could be the pivotal strategy to achieve the 2022 COVID-19 vaccination coverage target
por: Ayeni, Gabriel Omoniyi, et al.
Publicado: (2022)

Why do breakthrough COVID-19 infections occur in the vaccinated?
por: Maclean, Patrick, et al.
Publicado: (2021)

Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods
por: Smith, Trevor R. F., et al.
Publicado: (2017)

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines
por: Salvatori, Giovanni, et al.
Publicado: (2020)

A Global Comparative Evaluation of Commercial Immunochromatographic Rapid Diagnostic Tests for Visceral Leishmaniasis
por: Cunningham, Jane, et al.
Publicado: (2012)

Randomized COVID-19 vaccination rollout can offer direct real-world evidence
por: Hemkens, Lars G., et al.
Publicado: (2021)

Open access and open source in chemistry
por: Todd, Matthew H
Publicado: (2007)

The importance of addressing social inequalities and targeting the undecided to promote vaccination against COVID-19
por: Rozbroj, Tomas, et al.
Publicado: (2021)

BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy
por: Koti, Madhuri, et al.
Publicado: (2020)

Considerations for the rational design of a Chlamydia vaccine
por: Liang, Steven, et al.
Publicado: (2016)

Human leishmaniasis vaccines: Use cases, target population and potential global demand
por: Malvolti, Stefano, et al.
Publicado: (2021)

COVID-19 variants as moving targets and how to stop them by glycoengineered whole-virus vaccines
por: Galili, Uri
Publicado: (2021)

Open-source recombinant monoclonal secondary nanobodies
por: Ewers, Helge
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vmb3ar6qtrb037ng661q7ho6sg